Acute Myeloid Leukemia Clinical Trial

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Summary

The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid leukemia (AML) with one or more of the following criteria

CR 1 with poor risk features
CR 2, or higher order CR

Acute lymphoblastic leukemia (ALL) with one of the following criteria

CR 1 with poor risk features
CR 2, or higher order CR
Myelodysplasia, RAEB I
Donor has been identified
Age ≤ 65 years.
Performance Status 0-1.

Exclusion Criteria:

Patients relapsing <6 months after autologous SCT are not eligible.
Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.
Non-pregnant and non-nursing

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

9

Study ID:

NCT00593554

Recruitment Status:

Terminated

Sponsor:

Sherif S. Farag

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Indiana University Cancer Center
Indianapolis Indiana, 46202, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

9

Study ID:

NCT00593554

Recruitment Status:

Terminated

Sponsor:


Sherif S. Farag

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider